Methylphenidate (Ritalin, MPH) is the most commonly prescribed psychoactive drug for children. Used to treat attention-deficit/hyperactivity disorder (ADHD) and for cognitive enhancement in healthy individuals, its cellular mechanisms of action and potential long-term effects are poorly understood. We recently reported that a clinically relevant (1 mg/kg i.p., single injection) dose of MPH significantly decreased neuronal excitability in the juvenile rat prefrontal cortical neurons. Here we further explore the actions of acute treatment with MPH on the level of NMDA receptor subunits and NMDA receptor-mediated shortand long-term synaptic plasticity in the juvenile rat prefrontal cortical neurons. We found that a single dose of MPH treatment (1 mg/kg, intraperitoneal) significantly decreased the surface and total protein levels of NMDA receptor subunits NR1 and NR2B, but not NR2A, in the juvenile prefrontal cortex. In addition, the amplitude, decay time and charge transfer of NMDA receptor-mediated EPSCs were significantly decreased whereas the amplitude and short-term depression of AMPA receptor-mediated EPSCs were significantly increased in the prefrontal neurons. Furthermore, MPH treatment also significantly increased the probability and magnitude of LTP induction, but had only a small effect on LTD induction in juvenile rat prefrontal cortical neurons. Our data thus present a novel mechanism of action of MPH, i.e., changes in glutamatergic receptor-mediated synaptic plasticity following early-life treatment. Furthermore, since a single dosage resulted in significant changes in NMDA receptors, off-label usage by healthy individuals, especially children and adolescents, may result in altered potential for plastic learning.
Introduction
Attention deficit/hyperactivity disorder, or ADHD, is an increasingly common childhood disorder, and is now recognized in adults as well. ADHD is thought to affect between 3% and 5% of schoolaged children, although some estimates go as high as 8% (Faraone, Sergeant, Gillberg, & Biederman, 2003; Polanczyk, de Lima, Horta, Biederman, & Rohde, 2007) . Methylphenidate (Ritalin Ò , MPH) is the most commonly prescribed agent for treating ADHD (Challman & Lipsky, 2000) . It has been determined that MPH acts primarily on the dopaminergic and noradrenergic systems through blockade of the dopamine and norepinephrine reuptake transporters, thereby increasing the concentrations of these neurotransmitters in the brain to correct the attention deficits and hyperactivity (Arnsten & Pliszka, 2011; Berridge et al., 2006; Greenhill et al., 2006; Kuczenski & Segal, 2001 , 2002 .
Although MPH acts primarily on dopamine and norepinephrine, it likely has effects on other neurotransmitter systems, especially the glutamatergic system, to regulate attention, learning, and memory functions. In fact, the dopamine and glutamatergic systems are intricately interlinked, via intracellular signaling pathways as well as their physical interactions (Cepeda & Levine, 2006) . During development, NR2B-containing NMDA receptors are replaced by NR2A-containing ones (Cull-Candy, Brickley, & Farrant, 2001 ), raising the threshold for long-term potentiation (LTP) and lowering the threshold for long-term depression (LTD), making learning more selective (Kopp, Longordo, & Luthi, 2007; Yashiro & Philpot, 2008) . However, the prefrontal cortex (PFC) is unique among cortical regions in that it does not experience a significant alteration in the NR2A/NR2B ratio during development; thus, the potential for plasticity remains high throughout adulthood (Wang, Stradtman, Wang, & Gao, 2008) . NMDA receptors, due to their relationship with neural plasticity and learning/memory, are likely to be affected by stimulant drugs, including MPH. Indeed, the levels of NR2B have been shown to be decreased by treatment with amphetamine, a psychostimulant closely related to MPH (Mao et al., 2009 
